Fvii or fviia variants having increased clotting activity
CA 2502162 C · Owner: Maxygen Holdings Ltd. · Inventors: Haaning, Jesper Mortensen; Andersen, Kim Vilbour
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to novel Factor VII or VIIa variants comprising a substitution in at least one position selected from the group consisting of L39, 142, S43, K62, L65, F71, E82 and F275 which are positions involved in , tissue factor binding. Such variants exhibit increased clotting activity as compared to human wild-type Factor VIIa. The present invention also relates to use of such Factor VII or VIIa variants in therapy in particular for the , treatment of a variety of coagulation-related disorders.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 26, 2003 and granted April 15, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 26, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 26, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.